Sergey Jakimov
Co-Founder and Managing Partner @ LongeVC
Sergey Jakimov is a seed investor at LongeVC focused on Health Care and Life Science. Serial entrepreneur, having co-founded 3 deep-tech ventures and raised more than $50 million in venture funding for his own ventures and as an entrepreneur in residence. He has worked with several other early-stage companies in the therapeutics space on fundraising, IP protection, and clinical trial strategies, focusing on early treatments incardiovascular, oncology, and neurodegenerative spaces. Visiting Lecturer to several universities on VC and intellectual property rights, co-authored a master's program in Technology Law for the Riga Graduate School of Law.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Sergey Jakimov invests in
Stages Sergey Jakimov invests in
Countries Sergey Jakimov invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (67%)
- Life Science 2 (67%)
- Therapeutics 2 (67%)
- Biotechnology 2 (67%)
- Wellness 1 (33%)
Country
- Switzerland 1 (33%)
- United States 1 (33%)
- United Kingdom 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Valink Therapeutics is a health care drug discovery for next-generation cancer treatments. | $11.8M / Seed / Oct 20, 2025 | ||
| Catena Biosciences is a biotechnology company that offers protein conjugation, building biologic structures, and medical research. | $2.4M / Seed / May 10, 2024 | ||
| PreComb develops technologies to optimally adapt the therapies to each patient for difficult to treat cancers to increase the success rates in cancer therapy. Only an efficient use of healthcare resources can lead to a maximum improvement in the quality of life of patients. | $1.3M / Seed / Oct 04, 2022 |
Co-Investors
About LongeVC
LongeVC was created to support early-stage biotech and longevity-focused founders on their way to gain industrial momentum, raise capital, and grow to become the shapers of tomorrow's biotech industry.
LongeVC Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Garri Zmudze
Co-Founding Partner & Managing Partner
|
|||
Ilya Suharenko
Managing Partner and Co-Founder
|
|||
|
Sergey Jakimov
Co-Founder and Managing Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Sergey Jakimov invest in?
Sergey Jakimov invests primarily in Health Care, Life Science and Therapeutics startups, most often at Seed stage. Most of the 3 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Sergey Jakimov?
Public channels for Sergey Jakimov include LinkedIn and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Sergey Jakimov last invest?
The most recent investment recorded for Sergey Jakimov closed in Oct 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
